Interpace Diagnostics is a company focused on the development and commercialization of molecular diagnostic tests aimed to optimize patient diagnosis and management.
The company currently has three commercialized molecular tests: (1) PancraGen, for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts, (2) ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and (3) ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay.
PancraGEN is a unique, DNA-based, integrated molecular pathology test that assesses the risk of cancer in pancreatic cysts. The use of PancraGen as a first line test allows doctors and other clinicians to choose the most effective surgical option for patients with pancreatic cysts.
ThyGenX and ThyraMIR, when combined, can assess the risk of thyroid nodules as benign or malignant, thus reducing the amount of unnecessary surgeries. ThyGenX® is a mutational panel capable of highlighting common genetic alterations across 8 genes associated with papillary and follicular carcinoma. Similarly, ThyraMIR is the first miRNA gene expression classifier of its kind. It is based on an evaluation of 10miRNAs. The combination of these tests yield highly predictive results. ThyraMIR’s ability to identify malignancy in nodules that would be negative for ThyGenX improves the overall quality of results.
For more on Interpace, visit the company’s website.